Advertisement

Topics

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

09:37 EDT 14 Jun 2019 | ecancermedicalscience

Dr Kirsten Fischer presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the multinational, open-label, phase 3 CLL14 trial. Fixed-duration venetoclax plus obinutuzumab induced deep, high, and long lasting MRD-negativity...

Original Article: Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

NEXT ARTICLE

More From BioPortfolio on "Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...